Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin ‐induced apoptosis

ConclusionThe combined regimen of the proteasome inhibitor delanzomib with Dox chemotherapy may become an effective strategy for breast cancer therapy.

Source: Thoracic Cancer - March 17, 2019 Category: Cancer & Oncology Authors: Mopei Wang, Li Liang, Jiaxiong Lu, Yang Yu, Yanling Zhao, Zhenfeng Shi, Hui Li, Xin Xu, Yuxian Yan, Yan Niu, Zhentao Liu, Lin Shen, Hong Zhang Tags: ORIGINAL ARTICLE Source Type: research